Introduction {#s1}
============

Cisplatin and other related platinum drugs are common antineoplastic agents that are used in the treatment of a variety of cancers in both adults and children (for a review see Jamieson and Lippard, [@B18]). However, these drugs are associated with various side effects including nephrotoxicity and ototoxicity (for review see Rybak et al., [@B42]; Schacht et al., [@B45]; Karasawa and Steyger, [@B19]; Francis and Cunningham, [@B12]). Although nephrotoxicity can be managed to some extent (Cornelison and Reed, [@B7]; Wong and Giandomenico, [@B53]), mitigating ototoxicity in patients treated with cisplatin remains an unmet medical need (Brock et al., [@B2]; Schacht et al., [@B45]; Karasawa and Steyger, [@B19]). The platinum drugs act on cancerous cells mainly by forming adducts within the DNA (Huang et al., [@B16]; Jamieson and Lippard, [@B18]) and, possibly, by increasing reactive oxygen species (ROS) levels (Kopke et al., [@B22]; Rybak et al., [@B43]; Devarajan et al., [@B8]). In addition, cisplatin leads to cytotoxicity in normal cells that are not actively proliferating, inducing mitochondrial DNA damage and ROS elevation (Marullo et al., [@B29]; Wisnovsky et al., [@B52]).

Platinum-based antineoplastics irreversibly damage the cochlear hair cells starting in the basal turn---the outer hair cells appear to be more susceptible to this class of drug than other cell types in the cochlear duct, including the inner hair cells (Hinojosa et al., [@B15]; Li et al., [@B26]; Rybak et al., [@B44]). However, cisplatin-induced insult could extend beyond the hair cells and damage cells of the *stria vascularis*, a critical organ within the cochlea that is essential for maintaining the endocochlear potential and function of the cochlea (Laurell and Engstrom, [@B24]; Laurell et al., [@B23]). Although, damage to mostly outer hair cells is observed when low doses of cisplatin are used in rodents (Laurell and Engstrom, [@B24]; Cardinaal et al., [@B4]; Laurell et al., [@B25]; Park et al., [@B37]).

Routes of cisplatin entry into the hair cell could include the organic cation transporter Oct2 or the influx copper transporter Ctr1 (Riedemann et al., [@B41]; Ciarimboli et al., [@B6]; More et al., [@B32]; Xu et al., [@B54]). In addition, it was reported that in the absence of hair cell mechanotransduction (MET) cisplatin-induced hair cell death is reduced in zebrafish neuromast (Thomas et al., [@B49]; Stawicki et al., [@B48]). Gentamicin, which is bigger in size and weight than cisplatin, is known to permeate MET channels (Marcotti et al., [@B28]; Alharazneh et al., [@B1]; Vu et al., [@B51]); similarly, it is possible that cisplatin can permeate hair cell MET channels, although other routes could exist (Thomas et al., [@B49]). Using the zebrafish lateral line system, we test whether cisplatin affects hair cell MET currents, which might implicate its interaction with MET channels.

Attempts to find and develop otoprotective strategies for platinum-based drugs have been ongoing. One area of interest is antioxidant molecules. These include N-acetyl-cysteine (Feghali et al., [@B11]), alpha-lipoic acid (Kim et al., [@B21]), D-methionine (Lorito et al., [@B27]) and sodium thiosulfate (Muldoon et al., [@B33]). The most important consideration is to find a protection method or a drug that does not compromise the anti-tumor actions of the platinum-based drugs. For that reason, using mdivi-1, an inhibitor of the mitochondrial fission protein Drp1, could be a promising strategy to mitigate cisplatin-induced ototoxicity (Qian et al., [@B38]). One interesting aspect of mdivi-1 is that it has been reported to increase the apoptosis of tumor cells that are resistant to cisplatin (Qian et al., [@B39]). In general, mitochondrial dynamics were found to modulate antineoplastic activity of cisplatin (Qian et al., [@B38]; Han et al., [@B14]). Interestingly, cisplatin-induced tubular cell apoptosis and acute kidney injury were reduced by mdivi-1 (Brooks et al., [@B3]). Some recent work has shown promise for mdivi-1 in ameliorating the adverse effects of ototoxic aminoglycosides on hair cells of the inner ear (Nuttall et al., [@B36]). Here we test whether mdivi-1 could protect hair cells against cisplatin toxicity using the zebrafish lateral line system.

Materials and Methods {#s2}
=====================

Animals {#s2-1}
-------

Experiments were conducted using the Tübingen strain of zebrafish of either sex provided by the McDermott zebrafish core facility. Transgenic zebrafish stably expressing GFP in the hair cell body (*pvalb3b*::GFP) were previously generated (McDermott et al., [@B30]), and *cdh23^tj264a^* mutant (Söllner et al., [@B47]) was a kind gift from Dr. Teresa Nicolson (Oregon Health and Science University). Fish were maintained and bred at 28°C according to standard procedures (Nüsslein-Volhard and Dahm, [@B35]). This study was carried out in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and animal welfare guidelines of the Committee of Case Western Reserve University (CWRU), USA. The protocol was approved by the Institutional Animal Care and Use Committee at CWRU (Protocol Number: 2012-0187).

Cisplatin Treatment {#s2-2}
-------------------

Zebrafish larvae at days post fertilization (dpf) 5--6, were placed in varying concentrations of cisplatin (50--200 μM, ThermoFisher Scientific, Waltham, MA, USA) and/or mdivi-1 (1--10 μM, Enzo Life Sciences, Farmingdale, NY, USA) overnight for 16 h. The next day, the larvae were transferred to another dish, anesthetized with MS-222 (Sigma-Aldrich, St. Louis, MO, USA), and secured in a recording chamber using strands of dental floss tie downs (Ricci and Fettiplace, [@B40]) and placed under the microscope, an upright Olympus BX51WI microscope equipped with 100× 1NA objective for observation. To assess viability, blood flow and heart rate were visually monitored. Images were observed with a Grasshopper3 CMOS camera (Point Grey, Richmond, BC, Canada) and captured with manufacturer provided software. Starting with the eye neuromasts and moving caudal, the number of hair bundles were counted in approximately 10 neuromasts per fish.

FM1-43 Labeling and Image Analyses {#s2-3}
----------------------------------

After overnight treatment with cisplatin and/or Mdivi-1, fish were placed into wells containing FM1-43 (ThermoFisher Scientific, Waltham, MA, USA) in fish water. After 30 s, fish were transferred to fish solution containing MS-222 and BSA. The larvae were then secured in a recording chamber and placed under the microscope for imaging as described above. Approximately 3--4 neuromasts were imaged, and maximal projection images were generated using ImageJ (NIH, Bethesda, MD, USA). For lateral line neuromasts, raw images were gathered using an Olympus BX51WI microscope and a Grasshopper3 CMOS camera as described above. Fluorescence measurements were obtained using ImageJ. A region of interest was used to obtain measurements from the cells in each neuromast (I~cell~) and an area without cells (I~background~) in the same image. Fluorescence intensity of FM1-43FX (I~load~) for each neuromast was normalized (I~load~ = I~cell~ − I~background~).

Recordings of Neuromast Microphonic Potential in Zebrafish {#s2-4}
----------------------------------------------------------

We anesthetized zebrafish larvae (5--7 dpf) using MS-222 dissolved in a standard bath solution containing (in mM): NaCl (120), KCl (2), HEPES (10), CaCl~2~ (2), NaH~2~PO~4~ (0.7), adjusted to pH \~7.2. The larvae were secured in a recording chamber and placed under the microscope for observation as described above. Viability, blood flow and heart rate of larvae were visually monitored. Images were observed with a Grasshopper3 CMOS camera and captured with manufacturer provided software. We recorded from posterior neuromasts; kinocilia tufts were deflected with a fluid jet (Nicolson et al., [@B34]; Trapani and Nicolson, [@B50]) delivered via a glass pipette with a diameter of approximately 5--7 μm and controlled by HSPC-1 (ALA Scientific Instruments, Farmingdale, NY, USA). Fluid jet pipette was placed approximately 75 μm near the neuromast and used to deliver sinusoidal stimuli of 50 Hz frequency. The microphonic potentials were recorded at room temperature (22°C). We used borosilicate glass electrodes with a resistance of 3--6 MΩ, which were filled with standard bath solution and placed near the apical edges of the lateral line neuromasts. We recorded microphonic potentials using a PC-505B amplifier (Warner Instruments, Hamden, CT, USA) and a PCI-6221 digitizer (National Instruments, Austin, TX, USA). Microphonic potentials were amplified by 20 (SIM983, Stanford Research, Sunnyvale, CA, USA), measured by a jClamp (Scisoft, Yale University, New Haven, CT, USA) in a current-clamp mode, and low-pass filtered at 100 Hz. All records represent an average of at least 500 trials.

Statistics {#s2-5}
----------

All statistical analyses were performed using GraphPad Prism 7. Data are reported as mean ± SEM. Comparisons between groups were analyzed by ANOVA with Tukey *post hoc* testing.

Results and Discussion {#s3}
======================

Mechanotransduction Potentiates Cisplatin-Induced Hair Cell Death {#s3-1}
-----------------------------------------------------------------

Our data show that functional MET potentiate cisplatin-induced hair cell toxicity in lateral line neuromasts in a zebrafish (Figure [1](#F1){ref-type="fig"}), in accordance with published reports (Thomas et al., [@B49]; Stawicki et al., [@B48]). *cdh23^tj264a/tj264a^* mutant zebrafish do not have functional MET in hair cells, because Cdh23 is an integral part of mechanosensitive stereocilia bundles in hair cells (Siemens et al., [@B46]; Söllner et al., [@B47]; Kazmierczak et al., [@B20]; Indzhykulian et al., [@B17]). Notably, *cdh23* mutants have smaller numbers of hair cells per neuromast in comparison to wild-type or heterozygous fish (Figure [1](#F1){ref-type="fig"}). Despite the fact that treatment with 50 μM of cisplatin did not significantly change the number of hair cells in neuromasts of *cdh23^tj264a/tj264a^* zebrafish, whereas in wild-type fish this dose of cisplatin considerably reduced the number of hair cells (Figure [1A](#F1){ref-type="fig"}). This result indicates that MET channels may be involved in cisplatin entry into the hair cell. Alternatively, cisplatin entry into the hair cell is largely independent of the MET channel, but the ion flow carried out by functional MET potentiates cisplatin-induced damage.

![Mechanotransduction (MET) potentiates cisplatin-induced hair cell death. **(A)** Untreated *cdh23^tj264a/tj264a^* have fewer hair cells per neuromast when compared to wild-type and heterozygous fish. **(B)** When treated with increasing concentrations of cisplatin, *cdh23* mutants, which do not have functional MET, have significantly greater hair cell survival in comparison to wild-type or heterozygous animals, which have normal MET. Data are mean, error bars indicate SEM. \**p* \< 0.001, in comparison to wild-type and normal heterozygous larvae within the same treatment concentration. ^\#^*p* \< 0.001, in comparison to untreated controls within larvae of the same genotype (see Supplementary Table S1).](fncel-11-00393-g0001){#F1}

Cisplatin and Mechanotransduction in Neuromast Hair Cells {#s3-2}
---------------------------------------------------------

If cisplatin enters hair cells via MET channels, it could interact with the channel directly and attenuate ion flow through the channel. To test this hypothesis, the microphonic potentials of neuromast hair cells (Figures [2A,B](#F2){ref-type="fig"}) were measured with and without application of 50 μM or 100 μM of cisplatin. The microphonic potential is an evoked electrical potential elicited by hair bundle deflections. The microphonic potential results from modulation of the cationic current flowing into stimulated hair cells via functional MET channels. Our results show that microphonic potentials were not affected by cisplatin application (Figures [2A,B](#F2){ref-type="fig"}). An alternate approach using FM1-43FX was also employed to test the hypothesis. FM1--43FX is a derivative of FM1-43, an amphipathic styryl dye that is known to rapidly accumulate in sensory hair cells via the MET channels that are partially open at rest in non-stimulated hair bundles (Gale et al., [@B13]; Meyers et al., [@B31]). Loading of FM1-43FX in live hair cells of lateral line neuromasts of controls and after 100-μM-cisplatin was not significantly different (Figures [2C,D](#F2){ref-type="fig"}). Our results did not reveal any evidence that cisplatin enters hair cells via MET channels. It is known that aminoglycosides enter hair cells via MET channels and are permeant blockers of these channels. Our results, however, do not rule out the possibility cisplatin may enter hair cells via the MET channel but this amount may not be sufficient to affect measured microphonic potentials.

![Cisplatin does not affect MET in neuromast hair cells. **(A)** Neuromast microphonic potentials are not affected after 100-μM-cisplatin application. The top trace shows pressure applied to the stimulating puff pipette. **(B)** Summary of microphonic potential peak-to-peak amplitudes at twice the stimulus frequency obtained from lateral line neuromasts (controls and after 100-μM-cisplatin application). **(C)** Summary of fluorescent signal of FM1-43FX in live lateral line neuromasts of control and after 100-μM-cisplatin application. **(D)** Representative maximum-intensity projection images of FM1-43FX-treated live neuromasts: control and after 100-μM-cisplatin. Data are mean, error bars indicate SEM. *n* = 5--12 larvae (noted on bar graphs, from three to six clutches) per data point. Scale bar: 10 μm.](fncel-11-00393-g0002){#F2}

When MET is functional, substantial amounts of calcium can enter hair cells through MET channels. Intracellular calcium balance is critical for hair cell function; it was found that calcium homeostasis is rapidly disrupted following ototoxic aminoglycoside exposure (Esterberg et al., [@B9]). It is possible that hair cell mitochondria continuously buffer calcium entering cell via functional MET channels, causing hair cells to become more vulnerable to toxic insult. Drugs that could reduce mitochondrial stress and/or protect mitochondria in other ways, may potentially increase hair cell viability when faced with ototoxic drugs.

Mitochondrial Division Inhibitor 1 Protects against Cisplatin-Induced Hair Cell Death {#s3-3}
-------------------------------------------------------------------------------------

Here we tested whether mdivi-1 can protect hair cells against cisplatin induced toxicity in neuromast hair cells. Mdivi-1 is an inhibitor of mitochondrial division that selectively attenuates dynamin-related protein 1 activity, a fission protein that involved in the constriction and cleavage of mitochondria (Cassidy-Stone et al., [@B5]). First, we tested different doses of mdivi-1 for neuromast hair cell toxicity. High doses of mdivi-1, more than 10 μM, were toxic to the 5--6 dpf larvae (Figure [3A](#F3){ref-type="fig"}); therefore, we used lower doses of mdivi-1, 3 and 7 μM. Our data show that these doses of mdivi-1 protected hair cells of lateral line neuromast against toxicity of 50 μM of cisplatin (Figures [3B,C](#F3){ref-type="fig"}). These data demonstrated that modulating mitochondria dynamics may increase viability of hair cells against cisplatin toxicity in a zebrafish model. This finding is interesting also because it is known that mdivi-1 assists the abilities of cisplatin to trigger apoptosis in certain platinum-resistant tumor cells (Qian et al., [@B39]). Future studies, incorporating mammalian models, will be of further value in corroborating our results and revealing the mechanism of mdivi-1-mediated protection.

![Mdivi-1 protects against cisplatin-induced hair cell death. **(A)** Concentrations of mitochondrial division inhibitor mdivi-1 between 1--5 μM are well tolerated by zebrafish; whereas 10 μM of mdivi-1 is toxic to hair cells (*n* = 5 larvae per data point, from three clutches). **(B)** Application of 3 or 7 μM of mdivi-1 allowed significantly more hair cells to survive treatment with 50 and 100 μM of cisplatin. **(C)** Representative maximum-intensity projection images of *pvalb3b*::GFP neuromast hair cells treated with 50-μM-cisplatin and/or 50-μM-mdivi-1 (middle and right images). Data are mean, error bars indicate SEM. \*\**p* \< 0.001 and \**p* \< 0.05, in comparison to no mdivi-1 treatment within the same cisplatin concentration (see Supplementary Table S1). Scale bar: 10 μm.](fncel-11-00393-g0003){#F3}

Conclusion {#s4}
==========

MET potentiates cisplatin-induced damage of neuromast hair cells. However, cisplatin, in contrast to aminoglycosides, does not affect MET of neuromast hair cells. Our data suggests that mitochondrial protection may prevent cisplatin-induced damage to hair cells.
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